-
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Intelligent Non-invasive Diagnosis of Aneuploidy: Raw Values and Highly Imbalanced Dataset.
Neocleous A, Nicolaides K, Schizas C.
IEEE J Biomed Health Inform 2017;21:1271-1279. pdf -
First Trimester Noninvasive Prenatal Diagnosis: A Computational Intelligence Approach.
Neocleous AC, Nicolaides KH, Schizas CN.
IEEE J Biomed Health Inform 2016;20:1427-38. pdf -
Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies.
Stokowski R, Wang E, White K, Batey A, Jacobsson B, Brar H, Balanarasimha M, Hollemon D, Sparks A, Nicolaides K, Musci TJ.
Prenat Diagn 2015;35:1243-6. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:42-7. pdf -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:259-64. -
First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
Sonek J, Cicero S, Nicolaides K.
Am J Obstet Gynecol 2007;196:19. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Nicolaides KH.
Am J Obstet Gynecol 2004;191:45-67. -
Sonographic markers of fetal aneuploidy: a review.
Cicero S, Sacchini C, Rembouskos G, Nicolaides KH.
Placenta 2003;24:S88-98. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10. -
Absent nasal bone at 11-14 weeks of gestation and chromosomal defects.
Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:31-5. -
Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation.
Cicero S, Bindra R, Rembouskos G, Tripsanas C, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;11:400-2. -
Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study.
Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K.
Lancet 2001;358:1665-7. -
The 11-14 week scan.
Nicolaides KH, Heath V, Liao AW.
Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94. -
First-trimester ultrasound screening for chromosomal defects.
Snijders RJ, Johnson S, Sebire NJ, Noble PL, Nicolaides KH.
Ultrasound Obstet Gynecol 1996;7:216-26.